-
Something wrong with this record ?
One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases
J. Kosťun, KM. Ismail, M. Pešta, R. Slunečko, P. Stráník, V. Smoligová, J. Presl
Language English Country United States
Document type Journal Article, Comparative Study
Grant support
Cooperatio program, MATC science area
LX22NPO5102
National Institute for Cancer Research-NICR
European Union-Next Generation EU
NLK
Directory of Open Access Journals
from 2021
PubMed Central
from 2018
ProQuest Central
from 2020-08-01
Wiley-Blackwell Open Access Titles
from 2021
PubMed
39724456
DOI
10.1002/cnr2.70082
Knihovny.cz E-resources
- MeSH
- Sentinel Lymph Node Biopsy * MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local pathology genetics epidemiology MeSH
- Lymphatic Metastasis pathology diagnosis MeSH
- Endometrial Neoplasms * genetics pathology surgery MeSH
- Follow-Up Studies MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sentinel Lymph Node * pathology surgery MeSH
- Neoplasm Staging * MeSH
- Nucleic Acid Amplification Techniques * methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
AIMS: Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue. METHODS AND RESULTS: Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period. CONCLUSION: The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003120
- 003
- CZ-PrNML
- 005
- 20250206104042.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cnr2.70082 $2 doi
- 035 __
- $a (PubMed)39724456
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kosťun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic $1 https://orcid.org/0000000340779031 $7 xx0234946
- 245 10
- $a One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases / $c J. Kosťun, KM. Ismail, M. Pešta, R. Slunečko, P. Stráník, V. Smoligová, J. Presl
- 520 9_
- $a AIMS: Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue. METHODS AND RESULTS: Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period. CONCLUSION: The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory endometria $x genetika $x patologie $x chirurgie $7 D016889
- 650 12
- $a techniky amplifikace nukleových kyselin $x metody $7 D021141
- 650 12
- $a sentinelová uzlina $x patologie $x chirurgie $7 D000071036
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a staging nádorů $7 D009367
- 650 12
- $a biopsie sentinelové lymfatické uzliny $7 D021701
- 650 _2
- $a lymfatické metastázy $x patologie $x diagnóza $7 D008207
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lokální recidiva nádoru $x patologie $x genetika $x epidemiologie $7 D009364
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Ismail, Khaled M $u Department of Gynaecology and Obstetrics and Biomedical Center, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
- 700 1_
- $a Pešta, Martin $u Department of Immunochemistry, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň- Bory, Czech Republic $1 https://orcid.org/0000000181870566 $7 xx0073915
- 700 1_
- $a Slunečko, Robert $u Šikl's Department of Pathology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
- 700 1_
- $a Stráník, Petr $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
- 700 1_
- $a Smoligová, Vendula $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
- 700 1_
- $a Presl, Jiří $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
- 773 0_
- $w MED00209152 $t Cancer reports $x 2573-8348 $g Roč. 7, č. 12 (2024), s. e70082
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39724456 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104038 $b ABA008
- 999 __
- $a ok $b bmc $g 2263086 $s 1239127
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 7 $c 12 $d e70082 $e - $i 2573-8348 $m Cancer reports $n Cancer Rep (Hoboken) $x MED00209152
- GRA __
- $p Cooperatio program, MATC science area
- GRA __
- $a LX22NPO5102 $p National Institute for Cancer Research-NICR
- GRA __
- $p European Union-Next Generation EU
- LZP __
- $a Pubmed-20250121